HOXB3 and hepatocellular carcinoma: In conclusion, this study provides evidence that miR-375 released from BM-MSC-derived EV targets HOXB3 to inhibit its expression and then suppresses the downstream Wnt/β-catenin pathway activation, thereby inhibiting the malignant phenotypes of HCC cells (Figure 7).